ABC | Volume 114, Nº3, Março 2020

Artigo Original Silva et al. Ablação FA com Rivaroxabana Arq Bras Cardiol. 2020; 114(3):435-442 1. Calkins H, Hindricks G, Cappato R, KimYH, Saad EB, Aguinaga L, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECEexpertconsensusstatementoncatheter and surgical ablation of atrial fibrillation: Executive summary. Heart Rhythm. 2017;14(10):e445-94. 2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609-78. 3. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, et al. Periprocedural stroke and bleeding complications in patients undergoingcatheterablationofatrialfibrillationwithdifferentanticoagulation management: results from the role of Coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation(COMPARE)RandomizedTrial.Circulation.2014;129(25):2638-44. 4. Santangeli P, Di Biase L, Horton R, Burkhardt JD, Sanchez J, Al-Ahmad A, et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications evidence from a meta-analysis. Circulation: Arrhythm Electrophysiol. 2012;5(2):302-11. 5. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, DeenadayaluN, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants withwarfarin inpatientswithatrial fibrillation:ameta-analysisofrandomised trials. Lancet. 2014;383(9921):955-62. 6. Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015;36(28):1805-11. 7. Schulman S, Kearon C, Subcommitee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostaticmedicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-4. 8. Gautam S, John RM, Stevenson WG, Jain R, Epstein LM, Tedrow U, et al. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22(3):248-54. 9. Bassiouny M, Saliba W, Rickard J, Shao M, Sey A, Diab M, et al. Use of dabigatran for peri-procedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2013;6(3):460-6. 10. Yamaji H, Murakami T, Hina K, Higashiya S, Kawamura H, Murakami M, et al. Adequate initial heparin dosage for atrial fibrillation ablation in patients receiving non-vitamin K antagonist oral anticoagulants. Clin Drug Investig. 2016;36(10):837-48. 11. SilvaMA, Elias Neto J, Merçon ES, FuturoG, Kuniyoshi R. Ablação por cateter da FA sob uso ininterrupto de rivaroxabana (“abstract”). Arq Brasil Cardiol. 2017; 109(Suppl 2):27. 12. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart RhythmAssociation (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart RhythmAssociation, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society.. Heart Rhythm. 2012;9(4):632-96. 13. Di Biase L, Gaita F, Toso E, Santangeli P, Mohanty P, Rutledge N, et al. Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablationwith open irrigated catheters? Results froma prospective multicenter study. Heart Rhythm. 2014;11(5):791-8. 14. Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results fromamulticenter prospective registry. J AmColl Cardiol. 2012;59(13):1168-74. 15. Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial brillation: results fromamulticenter prospective regis- try. J AmColl Cardiol. 2014;63(10):982-8. 16. Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, et al. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N Eng J Med. 2017;376(17):1627-36. 17. Kirchhof P, Haeusler KG, Blank B, De Bono J, Callans D, Elvan A, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J. 2018;39(32):2942-55. 18. Reynolds MR, Allison JS, Natale A, Weisberg IL, Ellenbogen KA, Richards M, et al. A prospective randomized trial of apixaban dosing during atrial fibrillation ablation. The AEIOU Trial. JACC Clin Electrophysiol. 2018;4(5):580-88. 19. Vamos M, Cappato R, Marchlinski FE, Natale A, Hohnloser SH. Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri- procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Europace. 2016;18(12):1787-94. 20. Sawhney V, Shaukat M, Volkova E, Jones N, Providencia R, Honarbakhsh S, et al. Catheter ablation for atrial fibrillation on uninterrupted direct oral anticoagulants: a safe approach. Pacing Clin Electrophysiol. 2018 May 16; [Epub ahead of print]. Disponível em: https://onlinelibrary.wiley.com/doi/ full/10.1111/pace.13370. 21. SobolevM, Shiloh AL, Di Biase L, Slovut DP. Ultrasound-guided cannulation of the femoral vein in electrophysiological procedures: a systematic review and meta-analysis. Europace. 2017;19(5):850-5. 22. Yamagata K, Wichterle D, Roubicek T, Jarkovisky P, Sato Y, Kogure T, et al. Ultrasound-guided versus conventional femoral veinpuncture for catheter ablation of atrial fibrillation: a multicenter randomized efficacy and safety trial (ULTRA-FAST trial). Europace. 2018;20(7):1107-14. 23. Murakawa Y, Nogami A, Shoda M, Inoue K, Naito S, Kumagai K, et al. Nationwide survey of catheter ablation for atrial fibrillation: the Japanese catheter ablation registry of atrial fibrillation (J-CARAF)-A report on periprocedural oral anticoagulants. J Arrhythm. 2015;31(1):29-32. Referências Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 442